We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current NRXCF market cap is 231.95k. The company's latest EPS is CAD -0.0043 and P/E is -2.33.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 82k | 97k | 74k | 81k | 462k |
| Operating Income | -1.97M | -1.14M | -935k | -1.08M | -191k |
| Net Income | -2.38M | -1.61M | -1.95M | -1.57M | -771k |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 553k | 505k | 528k | 819k | 331k |
| Total Liabilities | 278k | 661k | 618k | 867k | 948k |
| Total Equity | 275k | -156k | -90k | -48k | -617k |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -2.05M | -1.24M | -1.52M | -1.04M | -165k |
| Investing | -28k | N/A | -110k | -107k | -5k |
| Financing | 1.99M | 966k | 1.64M | 1.17M | 315k |
| Market Cap | 231.95k |
| Price to Earnings Ratio | -2.33 |
| Price to Sales Ratio | 3.85 |
| Price to Cash Ratio | 10 |
| Price to Book Ratio | -2.89 |
| Dividend Yield | - |
| Shares Outstanding | 178.42M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 150 |
| 52 Week Change | -82.67% |
| 52 Week High | 0.01142 |
| 52 Week Low | 0.0012 |
| Spread (Intraday) | 0.01 (91.33%) |
| Company Name | Neutrisci International Inc (PK) |
| Address |
2200 – 885 west georgia street vancouver, british columbia V6C 3E8 |
| Website | https://www.neutrisci.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
